ALBPS Biophytis

Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of novel therapeutics for age-related diseases, today announced upcoming oral and poster presentations at the 2019 International Conference on Frailty and Sarcopenia Research (ICFSR 2019) being held from February 20 to 22, 2019 in Miami Beach, FL. The Company will present details of its lead clinical drug candidate, Sarconeos (BIO101), including its history and unique mechanism-of-action that targets the MAS receptor for the preservation of muscle function in muscle wasting disorders. Additionally, the Company will present the clinical trial design of its ongoing SARA Phase 2 study of Sarconeos (BIO101) in sarcopenia.

Stanislas Veillet, Ph.D., Chief Executive Officer of Biophytis said, “We are pleased to have been selected for three oral presentations and a poster at ICFSR 2019. We look forward to sharing the potential of Sarconeos (BIO101) for the treatment of sarcopenia and other muscular dystrophies with leading international clinicians and scientists from industry and academia. We believe Sarconeos (BIO101) is one of the most advanced drug candidates in clinical development for the treatment of sarcopenia, a severe geriatric muscle wasting condition with no currently approved medication.”

Details of the presentations are as follows:

Title:	Sarconeos (API BIO101) targets Mas receptor within the protective arm of the renin angiotensin system and proves efficacy in various models of muscle wasting.
Presenter:	Pierre Dilda, Ph.D.
Date/Time:	Wednesday, Feb. 20, 2019 / 5:30 pm EST
Additional Info:	Oral Communication 10
Title:	Insect Steroid Hormones as Human Medicine: Application to Sarcopenia and Muscle Dystrophies.
Presenter:	Stanislas Veillet, Ph.D.
Date/Time:	Thursday, Feb. 21, 2019 / 12:25 pm EST
Additional Info:	Oral Presentation at the Lunch Industry Symposium hosted by Biophytis
Title:	Designing a clinical program for BIO101, a Mas receptor activator to target age-related sarcopenia.
Presenter:	Waly Dioh, Ph.D.
Date/Time:	Thursday, Feb. 21 2019 / 12:25 pm EST
Additional Info:	Oral Presentation at the Lunch Industry Symposium hosted by Biophytis
Title:	Evaluation of safety and efficacy of BIO101, a new investigational drug for sarcopenia: a double-blind, placebo controlled, randomized clinical trial.
Presenter:	Waly Dioh, Ph.D.
Date/Time:	Thursday, Feb. 21, 2019
Additional Info:	Poster: Clinical Trials and Therapeutics P78

About BiophytisBiophytis is a clinical-stage biotechnology company focused on the development of novel therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Our therapeutic approach targets key biological resilience pathways that can protect against and counteract the effects of the multiple biological stresses that lead to age-related diseases.  Our lead drug candidate, Sarconeos (BIO101), is for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy. Our second drug candidate, Macuneos (BIO201), is for the treatment of retinopathies, including dry age-related macular degeneration (AMD) and Stargardt disease. Biophytis is based in Paris, France and in Cambridge, Massachusetts. For more information, please visit www.biophytis.com.

BIOPHYTIS is listed on the Euronext Growth market of Euronext Paris (ALBPS; ISIN: FR0012816825).

Follow us on Twitter @biophytis

BIOPHYTIS is eligible for the SMEs scheme

DisclaimerThis press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward looking statements, please refer to the Risk Factors (“Facteurs de Risque”) section of the Listing Prospectus upon the admission of Company’s shares for trading on the regulated market Euronext Growth of Euronext Paris filed with the AMF, which is available on the AMF website (www.amf-france.org) or at www.biophytis.com.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Biophytis in any country. Items in this press release may contain forward-looking statements involving risks and uncertainties. The Company’s actual results could differ substantially from those anticipated in these statements owing to various risk factors which are described in the Company’s prospectus. This press release has been prepared in both French and English. In the event of any differences between the two texts, the French language version shall prevail.

Biophytis Daniel SCHNEIDERMAN Chief Financial Officerdan.schneiderman@biophytis.comTel: +1 (646) 479-8060

U.S. Media ContactLifeSci Public RelationsCherilyn CECCHINI, M.D.ccecchini@lifescipublicrelations.comTel: +1 (646) 876-5196

Europe Media ContactCitigate Dewe RogersonLaurence BAULT / Antoine DENRYlaurence.bault@citigatedewerogerson.comantoine.denry@citigatedewerogerson.comTel: +33 (0)1 53 32 84 78Mob: +33(0)6 64 12 53 61